Managing Chemotherapy-Induced Nausea and Vomiting in a Patient on Highly Emetogenic Regimen
A 45-year-old woman with breast cancer is receiving her first cycle of AC chemotherapy (doxorubicin 60 mg/m² and cyclophosphamide 600 mg/m²), a highly emetogenic regimen. She has a history of motion sickness and morning sickness during pregnancy, both risk factors for chemotherapy-induced nausea and vomiting (CINV). She is anxious about nausea. The pharmacist must design a prophylactic antiemetic regimen and address breakthrough nausea.
1. Recommend an evidence-based prophylactic antiemetic regimen for the acute and delayed phases, including drug, dose, and schedule.
Read the worked answer
For highly emetogenic chemotherapy (HEC), guidelines recommend a 3-drug combination: a 5-HT3 receptor antagonist (e.g., ondansetron 16 mg oral or 8 mg IV on day 1), dexamethasone 12 mg oral/IV on day 1, and an NK1 receptor antagonist (e.g., aprepitant 125 mg oral on day 1, then 80 mg on days 2–3). For AC, which is moderately emetogenic but often treated as HEC, this triplet is appropriate. Add olanzapine 5 mg oral daily on days 1–4 as an option to improve control, especially given her risk factors. For delayed phase (days 2–4), continue dexamethasone 8 mg daily on days 2–3 (with aprepitant) and aprepitant 80 mg on days 2–3; 5-HT3 antagonist is not needed beyond day 1 for AC. Consider substituting oral ondansetron with granisetron or palonosetron if available. Ensure adequate hydration.
2. What rescue therapy would you recommend for breakthrough nausea and vomiting, and how would you adjust the prophylactic regimen for subsequent cycles?
Read the worked answer
For breakthrough CINV, add a drug from a different class not used prophylactically: e.g., olanzapine 5–10 mg oral daily (if not already used), or metoclopramide 10–20 mg every 6 hours, or prochlorperazine 10 mg every 6 hours. Avoid using a 5-HT3 antagonist for breakthrough if already used prophylactically within 6 hours. For subsequent cycles, if breakthrough occurs despite optimal prophylaxis, consider adding olanzapine to the prophylactic regimen, switching 5-HT3 antagonist to a longer-acting agent (palonosetron), or adding a second-generation NK1 antagonist. Also address anxiety with nonpharmacologic measures (relaxation techniques, ginger). Document response and tailor regimen.